Zebra Capital Management LLC acquired a new position in shares of Harvard Bioscience, Inc. (NASDAQ:HBIO) in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 14,595 shares of the medical instruments supplier’s stock, valued at approximately $45,000.

A number of other institutional investors have also added to or reduced their stakes in HBIO. Citigroup Inc. raised its position in shares of Harvard Bioscience by 231.2% during the fourth quarter. Citigroup Inc. now owns 13,600 shares of the medical instruments supplier’s stock worth $41,000 after acquiring an additional 9,494 shares during the last quarter. State Street Corp lifted its holdings in shares of Harvard Bioscience by 9.9% in the 4th quarter. State Street Corp now owns 42,254 shares of the medical instruments supplier’s stock valued at $129,000 after acquiring an additional 3,794 shares during the last quarter. Vivaldi Asset Management LLC bought a new position in shares of Harvard Bioscience in the 4th quarter valued at about $135,000. Marshall Wace LLP grew its position in Harvard Bioscience by 594.9% in the first quarter. Marshall Wace LLP now owns 86,543 shares of the medical instruments supplier’s stock worth $373,000 after acquiring an additional 74,089 shares in the last quarter. Finally, Greenwood Capital Associates LLC grew its position in Harvard Bioscience by 28.7% in the fourth quarter. Greenwood Capital Associates LLC now owns 125,958 shares of the medical instruments supplier’s stock worth $384,000 after acquiring an additional 28,074 shares in the last quarter. Institutional investors own 62.93% of the company’s stock.

Shares of Harvard Bioscience stock traded up $0.20 during trading on Thursday, hitting $2.30. 362,816 shares of the stock were exchanged, compared to its average volume of 141,597. The stock’s fifty day moving average is $2.55 and its 200 day moving average is $2.86. The stock has a market cap of $75.16 million, a PE ratio of -17.69 and a beta of 1.25. The company has a debt-to-equity ratio of 0.67, a quick ratio of 1.24 and a current ratio of 2.12. Harvard Bioscience, Inc. has a 12 month low of $1.39 and a 12 month high of $4.66.

Harvard Bioscience (NASDAQ:HBIO) last issued its quarterly earnings data on Wednesday, February 26th. The medical instruments supplier reported $0.08 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.07 by $0.01. Harvard Bioscience had a negative net margin of 4.03% and a positive return on equity of 5.94%. The firm had revenue of $30.97 million for the quarter, compared to the consensus estimate of $30.80 million. Sell-side analysts anticipate that Harvard Bioscience, Inc. will post 0.17 EPS for the current fiscal year.

A number of equities analysts have recently issued reports on the stock. Zacks Investment Research upgraded shares of Harvard Bioscience from a “hold” rating to a “buy” rating and set a $3.75 price objective on the stock in a research note on Tuesday, March 3rd. TheStreet cut shares of Harvard Bioscience from a “c-” rating to a “d+” rating in a research report on Monday, February 10th. Finally, Benchmark lifted their target price on shares of Harvard Bioscience from $3.50 to $4.00 and gave the company a “speculative buy” rating in a report on Thursday, February 27th. Three research analysts have rated the stock with a hold rating and one has assigned a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and an average price target of $3.25.

Harvard Bioscience Profile

Harvard Bioscience, Inc provides scientific instruments, systems, software, and services used in life science basic research, drug discovery, and clinical and environmental testing. The company offers physiology, cell, and molecular instruments, such as traditional syringe pump and peristaltic pump products, as well as a range of instruments and accessories for tissue, organ, and animal based lab research under the Harvard Apparatus, CMA Microdialysis, Panlab, Coulbourn, and Hugo Sachs brands; and spectrophotometers, microplate readers, amino acid analyzers, gel electrophoresis equipment, sample preparation plates and columns, and electroporation and electrofusion instruments under the Biochrom, BioDrop, Hoefer, Scie-plas, QuikPrep, and BTX brands.

Featured Article: Overbought

Want to see what other hedge funds are holding HBIO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Harvard Bioscience, Inc. (NASDAQ:HBIO).

Institutional Ownership by Quarter for Harvard Bioscience (NASDAQ:HBIO)

Receive News & Ratings for Harvard Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Harvard Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.